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The crystal structure of coxsackievirus A9: new insights into the
uncoating mechanisms of enteroviruses
Elaine Hendry1†¶, Hideki Hatanaka1‡¶, Elizabeth Fry1‡, Michael Smyth1§,
John Tate1#, Glyn Stanway2, Juhana Santti3, Marita Maaronen3, Timo Hyypiä3,4
and David Stuart1,5‡
Background: Coxsackievirus A9 (CAV9), a human pathogen causing
symptoms ranging from common colds to fatal infections of the central nervous
system, is an icosahedral single-stranded RNA virus that belongs to the genus
Enterovirus of the family Picornaviridae. One of the four capsid proteins, VP1,
includes the arginine-glycine-aspartate (RGD) motif within its C-terminal
extension. This region binds to integrin αvβ3, the only receptor for CAV9 to be
conclusively identified to date.
Results: The crystal structure of CAV9 in complex with the antiviral compound
WIN 51711 has been solved to 2.9 Å resolution. The structures of the four
capsid proteins, VP1 to VP4, resemble those of other picornaviruses. The
antiviral compound is bound in the VP1 hydrophobic pocket, and it is possible
that the pocket entrance contains a second WIN 51711 molecule. Continuous
electron density for the VP1 N terminus provides a complete picture of the
structure close to the fivefold axis. The VP1 C-terminal portion is on the outer
surface of the virus and becomes disordered five-residues N-terminal to the
RGD motif.
Conclusions: The RGD motif is exposed and flexible in common with other
known integrin ligands. Although CAV9 resembles coxsackie B viruses (CBVs),
several substitutions in the areas implicated in CBV receptor attachment
suggest it may recognise a different receptor. The structure along the fivefold
axis provides new information on the uncoating mechanism of enteroviruses.
CAV9 might bind a larger natural pocket factor than other picornaviruses, an
observation of particular relevance to the design of new antiviral compounds.
Introduction
Coxsackievirus A9 (CAV9) is a picornavirus of the genus
Enterovirus. Classification based on pathology and serol-
ogy has identified 23 coxsackie A virus (CAV) and six
coxsackie B virus (CBV) serotypes, however CAV9 is
genetically more similar to CBVs and echoviruses than to
other CAVs [1]. CAV9 infects humans and is one of the
most frequently isolated CAVs, causing a broad range of
symptoms from mild cold-like illnesses to fatal infections
of the central nervous system [2]. 
There are six genera in the picornavirus family: the
enteroviruses, rhinoviruses, aphthoviruses, cardioviruses,
hepatoviruses and parechoviruses. Atomic-resolution
structures have been solved for representatives of four out
of the six genera [3–6], all of which are broadly similar.
The non-enveloped particles are composed of four viral
proteins (VPs) that make up a 30nm diameter capsid
which surrounds approximately 7500 nucleotides of
single-stranded RNA. The capsid possesses icosahedral
symmetry, being made up of 60 copies each of the four
viral coat proteins VP1 to VP4 which are arranged in T = 1
(pseudo T = 3) symmetry. VP1, VP2 and VP3 each
contain in the order of 270 amino acid residues, folded
into eight-stranded antiparallel β-sheet structures with a
jelly-roll topology, and form the outer surface of the virus.
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VP4 contains only about 70 amino acids, and lies on the
inside of the capsid. The major differences among the
picornavirus structures occur in the surface-exposed loop
regions, which define the receptor-binding and principle
antigenic sites, and on the inner surface of the virion. 
One of the first picornavirus structures to be solved was that
of human rhinovirus 14 (HRV14) [6]. This analysis revealed
a canyon surrounding each fivefold axis that is wide enough
to bind intercellular adhesion molecule-1 (ICAM-1), the
cellular receptor, but too narrow to bind an antibody. It was
proposed in the canyon hypothesis [7] that this spatial seclu-
sion of a necessarily conserved receptor-binding site might
be a general strategy facilitating viral escape from immune
surveillance. It was later shown that ICAM-1 does indeed
bind into the canyon of HRV16 [8]. However, the structure
of foot-and-mouth disease virus (FMDV) suggested that
alternative strategies might be used for receptor attachment
[5,9], and peptide–antibody complexes for this system
[10,11] demonstrate that seclusion of receptor-binding
residues is not a general requirement [12], a view supported
by the structure of an antibody–HRV14 complex [13].
Alignments of enterovirus sequences show that CAV9 pos-
sesses an approximately 15 amino acid insertion at the C ter-
minus of VP1 which contains an arginine-glycine-aspartate
(RGD) tripeptide [1], a motif known to interact with inte-
grins [14]. Analysis of CAV9 sequences isolated over a 25
year period show that the RGD motif is conserved but most
of the surrounding residues are variable [15], implying that
the tripeptide has a functional role. Binding experiments
have shown that RGD-containing peptides block CAV9
infectivity in green monkey kidney (GMK) cells [16] and
the cellular receptor has been identified as the integrin αvβ3
[17], also known as the vitronectin receptor. CAV9 mutants
lacking the RGD motif have a small-plaque phenotype in
monkey kidney cells, but in human rhabdomyosarcoma
(RD) cells infectivity is the same as with RGD-containing
viruses [18]. This suggests an alternative receptor-binding
site which is evidently more important in RD cells. A recent
study on the kinetics of uncoating has confirmed that there
are two different entry routes into host cells, only one of
which is dependent on the RGD sequence [19].
The virus most similar to CAV9 (based on RNA sequence)
for which there is a known three-dimensional structure is
coxsackievirus B3 (CBV3) [20]. CBV3 uses two different
receptors, coxsackie and adenovirus receptor (CAR) [21]
and decay accelerating factor (DAF) [22]. On the basis of
the extent of conservation of surface residues, it has been
proposed that the canyon and the twofold depression are
binding sites for CAR and DAF, respectively [20].
In order to be capable of disassembly and yet maintain sta-
bility outside the host, the virus must be able to make a trig-
gered conformational change. In the case of enteroviruses
and rhinoviruses, uncoating is believed to occur by the for-
mation of A particles [23], virions with an altered structure
that have been observed by electron microscopy. Three fea-
tures of viral structure have been discussed as potential
modulators of uncoating: a hydrophobic pocket, in VP1,
under the base of the canyon that can bind so-called pocket
factors thus stabilising the capsid [24,25]; a myristoyl group
bound to the N terminus of VP4 that may insert into the
host membrane [26]; and  ions on the fivefold axis that may
respond to the change in pH of the endocytotic vesicle and
allow extrusion of the RNA through the vertex of the five-
fold axis [27]. Although the nature of the events leading to
uncoating remains unclear, compounds that bind tightly
within the VP1 pocket inhibit uncoating and represent
potential therapeutic agents. An example of such a com-
pound is WIN 51711 [28].
Here we report the 2.9 Å resolution structure of CAV9 in
complex with WIN 51711. Electron density for the C ter-
minus of VP1 is clear up to six residues prior to the RGD
motif, so although we cannot visualise this site its approxi-
mate location can be inferred. Several unexpected fea-
tures are presented here, such as additional WIN
molecule-like density at the mouth of the pocket, the first
continuous model of the VP1 N terminus of an
enterovirus, and ion-like spherical electron densities along
the fivefold and threefold axes.
Results and discussion
Overall structure
The data set was 41.1% complete with an overall R merge
of 17% (Table 1). The structure was solved by molecular
replacement and refined using strict noncrystallographic
constraints, see the Materials and methods section. The
electron-density maps were of good quality. A sample
region of the final 2Fo–Fc map for part of VP2 is shown in
Figure 1. The final R factor for the model was 16.9%. In
light of the excellent ratio of X-ray observations to para-
meters (373,000 reflections and 6540 atoms), the good
stereochemistry of the model (root mean square deviation
[rmsd] for bond lengths 0.012 Å), and the satisfactory
backbone torsion angles (87.3% of the residues lie in the
most favoured region of the Ramachandran plot that the
program PROCHECK [29] produced), the model can be
considered as essentially refined. The structure of a pro-
tomer is shown in Figure 2. The secondary structures,
solvent accessibility and sequence conservation between
CAV9 and CBVs are summarised in Figure 3.
As the structural analysis suggested some disagreement
between the electron-density map and the original amino
acid sequence deduced from the CAV9 cDNA clone [1],
the capsid protein-coding region of the clone was rese-
quenced. Comparison between the sequences showed
eight amino acid differences; these residues were found in
VP1 at positions 11 (Arg/Val original/new sequence),
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12 (Cys/Val), 13 (Thr/His), 20 (Thr/Ser), 84 (Lys/Asn), 85
(His/Asp) and 142 (Arg/His). In addition, a residue at posi-
tion 110 of VP2, which was leucine in the database
sequence but valine in the original article [1], turned out
to be valine in this analysis. The electron density is
entirely consistent with the new sequence.
Superimpositions with other picornavirus structures are
shown in Figure 4. Table 2 shows quantitatively the struc-
tural similarities between CAV9 and some other picor-
naviruses. Amongst the enteroviruses, CAV9 is most similar
to CBV3 and least similar to bovine enterovirus (BEV).
Slightly more similar than BEV is HRV14, which belongs
to a different genus. The capsid region sequence identities
of BEV and HRV14 to CAV9 are 73.1% and 79.5%, respec-
tively, which also questions the classification of BEV. As
expected Mengo virus in the cardiovirus genus and FMDV
in the aphthovirus genus are the most distant from CAV9.
VP1
VP1 contains 299 residues, of which the first 284 have
been built into the map. The β-barrel structure of known
picornavirus structures is well conserved with eight
β strands (B–I), however, some loop regions adopt distinct
conformations (Figure 4a). In particular, the three loops
that cluster at the fivefold axis (the BC, DE and HI loops;
residues 81–89, 128–140 and 224–231) vary most in struc-
ture from those of CBV3. The BC loop has a three-residue
insertion in CAV9 relative to CBV3.
The N-terminal 12 amino acids were not present in the
phasing model, and were built into the map after two
rounds of modelling and refinement. The N terminus
forms a finger that points towards the base of the fivefold
axis (Figure 4a), in a similar position to the tentative
models of poliovirus VP1 N-terminal segments [24], which
were given an arbitrary sequence. There are mainchain
hydrogen bonds between the VP1 residues 2–6 and the
VP4 residues 3–5, characteristic of a parallel β sheet,
which may explain why both VP4 and the N terminus of
VP1 are found to be externalised in A particles.
The CAV9 electron-density map shows ordered density up
to residue 284 of VP1, that is, six residues before the RGD
motif and 15 residues before the C terminus of the protein.
This implies that, in common with the structure of the RGD
loop in FMDV [5], the sequence does not form a single con-
formation. Residues 282–284 differ from the VP1 C-terminal
residues of CBV3, detaching themselves from the outer
surface of the virion near the C strand of the VP3 β barrel.
VP2
The β barrel follows the same path as that of other VP2
structures, the largest feature being the ‘puff’ region made
up of the EF loop (residues 129–178). Of the 261 residues
of VP2, all but the N-terminal nine residues are present in
the model. The N terminus starts on the inner side of the
capsid towards the icosahedral threefold axis and finishes
exposed to the surface close to the twofold axis. The least
conserved area of the structure with respect to CBV3 is
the puff, and this region has been implicated in receptor
binding in poliovirus [30] (Figure 4b). The puff is made
up of two sequential loops, and the second is more
exposed on the virus surface. In CAV9 there is a two-
residue deletion in the second loop compared to CBV3.
Pro83 is clearly a cis proline (Figure 1), although it was
assigned as trans in the CBV3 structure, which was used
for the initial model for molecular replacement. This
proline is perfectly conserved among picornaviruses [31],
and adopts a cis conformation even in HRV14, Mengo
virus and FMDV [31,32]. Therefore, we suggest that it is a
general feature of picornaviruses. It has been suggested
that isomerisation of this proline residue might influence
neighbouring structural features, such as the orientation of
helix A involved in pentamer–pentamer interactions [31].
VP3
VP3 contains 238 residues, all of which are modelled into
the structure (Figure 4c). The conserved β barrel is 
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Table 1
Data collection and refinement statistics.
Data collection and processing
Dmin (Å) 2.9
Number of crystals 8
Number of images 92
Number of reflections 697,000
Number of unique reflections 290,000
R merge (%)* 17
Completeness (%)† 41
I/σ(I) 4.2
Correlation coefficient (%)‡ 88.7
Refinement
Data range (Å) 20–2.9
Final statistics
R factor (%)§ 16.9
Protein model 6540 Atoms
843 Residues
Solvent 448 Water molecules
Nonprotein atoms 15 (Myristoyl groups)
50 (2 WIN molecules)
Rmsd bond lengths (Å)# 0.012
Rmsd angles (°)# 1.79
Rmsd B (bonded; Å2)¶ 3.7
Rmsd B (angle-related; Å2)¶ 5.4
Mean overall B factor for 23.8
mainchain atoms (Å2)
*R = 100 × ∑h ∑j Ih, merged–Ih, j / ∑h N|Ih, merged, where j = 1,
…, N for N data sets. †Completeness of the highest resolution shell
(3.1–2.9 Å) was 32%. ‡Correlation coefficient = 100 × ∑h
(< Fobs > –Fh, obs)(< Fav >–Fh,av) / [∑h (< Fobs > –Fh, obs)2 ×
∑h (< Fav > –Fh, av)2]1/2. §R = 100 × ∑h Fh, obs–Fh,calc / ∑hFh,obs. #Root mean square deviation (rmsd) from ideal bond lengths
or bond angles. ¶Rmsd of B factors for the bond or angle restraints.
relatively compact, and an extended N-terminal tail
begins close to the fivefold axis, stacked above the
N termini of VP1 and VP4 bringing it closer to the outer
surface. The fivefold related N termini form a β cylinder,
which is likely to be important in pentamer formation
and stability. On the other hand the VP3 C terminus
appears on the virus surface. The most prominent surface
protrusion is the ‘knob’ formed by residues 58–69. This
loop is also the most variable in structure compared with 
other picornaviruses.
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Figure 1
Stereoview of a sample region of the 2Fo–Fc
map from CAV9 VP2 contoured at 3σ, shown
as black mesh with the atoms of CAV9
connected by thick grey rods. The figure was
generated using a version of MOLSCRIPT
[51] modified by R Esnouf (BOBSCRIPT
[52,53]) and Raster3D [54].
Figure 2
Structure of a CAV9 protomer unit. The different viral proteins are colour-
coded: blue, VP1; green, VP2; red, VP3; yellow, VP4. (a) Stereoview Cα
trace, dotted every tenth residue and numbered every twentieth residue.
(b) Ribbon depiction illustrating the secondary structure elements. Major
secondary structure elements are labelled, with β strands BIDG and
CHEF forming opposing β sheets and flanking helices prefixed by ‘h’.
The fivefold, threefold and twofold axes are shown by dotted lines and
labelled with a pentagon, a triangle and an oval, respectively. The figure
was generated using a version of MOLSCRIPT [51] modified by R
Esnouf (BOBSCRIPT [52,53]) and Raster3D [54].
VP4
VP4 is the most conserved of all the viral proteins and lies
on the interior of the capsid (Figure 4d). After two rounds
of modelling and refinement nearly all the structure could
be modelled into the density, with the exception of the
loop region from 16–22 corresponding to the most variable
sequence. The 69 amino acid chain has little secondary
structure, beginning close to the icosahedral fivefold axis
and snaking towards the threefold axis. The N-terminal
glycine is covalently attached to a myristic acid moiety by
an amide linkage, and the myristoyl groups cluster around
the fivefold axis underneath the VP3 β cylinder. The car-
boxylate group of the lipid forms a hydrogen bond with
Thr28 of VP4. The C terminus of VP4 is close to the
N terminus of VP2, but because the nine residues at the
start of VP2 are not visible it is not possible to define the
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Structure
The sequence of the capsid region of CAV9 aligned with that of
CBV3. The alignment was made using CLUSTAL-W [55] and
corrected by eye and by using structural alignment with SHP [56].
Residues conserved among CAV9, CBV3 and other CBVs are shown
boxed with a black background. Helices and strands, assigned
manually, are labelled and represented by squiggles and arrows,
respectively. Solvent accessibility was calculated by DSSP [57] in the
presence of neighbouring symmetry-related protomers, and is shown
by the darkness of bars below the sequence; black with a relative
accessibility > 40% and grey > 10%. Residues located on the external
virion surface are shown by black triangles. The bottom row marks with
grey and black ovals those residues for which the Cα distance
between CAV9 and CBV3 is larger than 0.5 and 1.0 Å, respectively;
asterisks are added where one of the two structures is missing. This
figure was produced using the program ESPript [58].
precise relationship between the two termini which are
covalently linked prior to cleavage of VP0, the final step in
the maturation of the virion. 
Visible RNA
A region of density resembling an RNA nucleotide is seen
interacting with the inner surface of the protein shell,
making a ring-stacking interaction with Trp38 of VP2. This
residue is highly conserved amongst the picornaviruses, and
similar density, possibly corresponding to a purine base, is
seen in other structures in this position [20,24,32,33]. 
Surface characteristics and receptor binding
Around each fivefold protrusion there are five distinct
depressions ~15 Å deep (Figures 5a–c), rather than a con-
tinuous circular canyon. The structure forming a ridge
between each depression is composed of the C terminus
of VP3, the first loop of the puff of VP2, and residues of
C-terminal loop (around residue 260) of VP1. The ridges
are curved giving the surface of the pentamer the appear-
ance of a propeller. The depression on the icosahedral
twofold axis, also ~15 Å deep, is enclosed by four walls
made up of symmetry-related pairs of VP3 and VP2.
In CAV9, the RGD motif (residues 290–292) lies approxi-
mately centrally within the 15-residue C-terminal exten-
sion of VP1, which is not visible in the structure. Six
residues N-terminal to this region, residue 284 can be
visualised on the surface of the virus. There is a negatively
charged patch close to residue 284 of VP1 (Figure 5b),
which may interact with the triple arginine motif which
precedes and overlaps the RGD motif. This patch
includes Asp182 and Glu183 (VP3) and is adjacent to the
drug-binding site located at the centre of the canyon
depression. This would enable Asp292 in the RGD motif
to contact Arg205 (VP1), a positively charged residue on
the structure separating the canyon and twofold depres-
sions. We find continuous weak electron density starting
1532 Structure 1999, Vol 7 No 12
Figure 4
Stereoview superimpositions of the CAV9
structure with those of other picornaviruses.
(a) VP1, (b) VP2, (c) VP3 and (d) VP4. The
structures are colour-coded: black, CAV9; red,
CBV3; blue, type-1 poliovirus; green, HRV14;
yellow, BEV. PDB entries used are shown in
Table 2, and superimposition was made using
SHP [56]. Parts (a), (b) and (c) are oriented so
that the closest fivefold axis is vertical and the
twofold axis is in the plane. In (d), VP4 proteins
are rotated by 90° so that the fivefold axis is
perpendicular to the paper. The figure was
generated using a version of MOLSCRIPT
[51] modified by R Esnouf (BOBSCRIPT
[52,53]) and Raster3D [54].
from above Arg205 (VP1) running along the wall of the
canyon depression up to His218 (VP1) (data not shown),
but it is too ambiguous to discriminate from solvent or to
build a model of the C-terminal segment of VP1. 
Thus, the terminal 15 residues of VP1 do not form an inte-
gral part of the virus structure, in line with the observed
viability of mutants lacking this region [18]. Many of the
structurally characterised integrin ligands [5,34,35] present
the RGD motif in an exposed mobile loop, and this mobil-
ity may be important in ligand binding.
Although the RGD motif is essential for binding to inte-
grins, it is likely, by analogy with better studied
integrin–ligand pairs, that attachment will also involve
other portions of the virion surface. For example, a site on
one FNIII domain of fibronectin synergises with an adja-
cent domain bearing the RGD to form the integrin-
binding site [36]. Figure 5b shows two patches crowded
with charged residues: one is located around the fivefold
axis and close to the surface above the WIN molecule
bound in the pocket, and the other surrounds the icosahe-
dral twofold axes. These charged patches might con-
tribute to integrin binding or could bind another receptor
molecule (e.g. in FMDV, another αvβ3 binding picor-
navirus, a highly charged surface patch binds heparin [9]).
However, we cannot find any area of particularly intense
electrostatic potential (data not shown).
When the structure of CBV3 was determined, it was pro-
posed, on the basis of conservation among CBVs, that the
canyon and twofold depressions (Figures 5d–f) were the
respective binding sites for CAR and DAF. In the case of
CAV9, one receptor has been identified as integrin αvβ3,
but other receptor(s) have not been characterised and it is
unclear whether CAR or DAF could also be receptors for
CAV9. Figure 5f shows the contribution to the virion
surface made by residues conserved among CBVs, and
Figure 5c shows that inclusion of CAV9 into the comparison
markedly reduces the conserved surface areas. In CAV9
more residues are replaced on the floor of the canyon
depression, especially adjacent to the pocket, than are sub-
stituted on the floor of the twofold depression, which might
suggest that CAR does not bind to CAV9. The remaining
conserved residues are located mainly on the border
between the biological protomers, implying that these
residues might have a role in the process of virus assembly.
The antiviral compound
All of the rhinoviruses and enteroviruses of known struc-
ture possess a hydrophobic pocket under the base of the
canyon of VP1, which extends from a pore on the virus
surface through the interior of the β barrel until it is closed
off by loops of VP1. This pocket is thought to be occupied
by a natural lipid pocket factor upon release of the virus
from an infected cell. In some structures this pocket factor
is present, in others its place has been taken by a single
antiviral compound, and in the case of HRV14 the pocket
is empty [6,32]. It is thought that a kinetic equilibrium
exists between occupied and unoccupied pocket states
and that the presence of a pocket factor or drug inhibits
uncoating [37]. The inhibition could be caused by preven-
tion of the collapse of the hydrophobic pocket or by block-
ing the flow of ions into the virus interior by increasing the
rigidity of the ion ligands. The release of the pocket factor
allows the virus structure to ‘breathe’, presumably allow-
ing the conformational changes necessary for uncoating to
be transmitted to the structure surrounding the fivefold
axis. In contrast the aphthovirus and cardiovirus genera of
the Picornaviridae have no hint of, nor room for, a pocket
factor. These viruses presumably have no need for such a
factor as they have a different mechanism of uncoating,
dissociating via pentamers instead of A particles [38]. 
CAV9 was propagated, purified and crystallised in the
presence of the antiviral compound WIN 51711
(Figure 6), indeed it was not possible to reproducibly
obtain crystals otherwise. A WIN 51711 molecule is
observed in the CAV9 pocket, with the bulkier 4-oxa-
zolinylphenoxy group at the closed end and the smaller
3-methylisoxazole group tucked into the open end
(Figure 6a). From the electron density we cannot rule out
the possibility that a fraction of molecules bind in the
opposite orientation. The predominant orientation for
WIN 51711 is the same as that observed in both HRV14
and type-3 poliovirus [39,40], however, the addition of a
single methyl group to the oxazoline ring is sufficient to
reverse the orientation in HRV14 [39]. A related but
shorter compound (WIN 66393) soaked into CBV3 crys-
tals [20] binds the same way round as for CAV9, with the
bulkier double ring in the closed end of the pocket. The
dimensions of the pocket are very similar in both the
CAV9 and CBV3 structures, the major exception being a
threonine at residue 97 (VP1) in CAV9 that interacts with
the isoxazole ring in place of a proline in CBV3.
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Table 2
Comparison of the structure of CAV9 with those of other
picornaviruses.
PDB entry Number of Rms distance Sequence
equivalent of Cα identity for
residues atoms (Å)* equivalent
residues (%)
CBV3 1cov 794 0.62 75.4
Polio1 2plv 787 0.94 56.0
HRV14 1r08 750 0.85 50.1
BEV 1bev 734 0.98 48.0
Mengo 1mec 592 1.34 29.1
FMDV 1fmd 518 1.33 23.7
*Superimpositions were performed using the program SHP [56]; rms,
root mean square.
It was a surprise to find additional electron density in the
vicinity of the entrance to the pocket factor binding site.
This density was present in all the electron-density maps
calculated and, although at a relatively low level, was con-
sistent in shape between different maps. The density is
shown in Figure 6a. We cannot provide a definitive identi-
fication of the chemical moiety that this feature repre-
sents, however, the general shape does not appear to be
consistent with it being polypeptide (C-terminal residues
of VP1 might conceivably have attached here, but the dis-
tinctive amino acid sequence of this region is not seen).
An alternative explanation is that the density might be
due to a series of water molecules or possibly dimethyl-
sulphoxide that the WIN compound was dissolved in.
Once again we do not feel that these provide a satisfactory
explanation for the observed electron density. In fact the
density appears to be most satisfactorily explained by a
second copy of WIN 51711, blocking the entrance to the
hydrophobic pocket. This is the first report for the associa-
tion of more than one inhibitor for each copy of VP1.
This second or ‘mouth’ WIN molecule appears to lie head-
to-head with respect to the standard or ‘pocket’ WIN mol-
ecule, with the single rings interacting with each other
(Figure 6). The double ring of the ‘mouth’ WIN emerges at
the base of the canyon depression slightly exposed to the
solvent. This region of the surface appears at first sight to
be quite hydrophilic, however, in the presence of this
bound moiety the surrounding sidechains are arranged so as
to make a binding site with considerable hydrophobic char-
acter. There are a total of 11 hydrophobic interactions
(including those from an adjacent protomer). Residues con-
tributing to these interactions include Leu216 (VP1),
Leu178 (VP3), the aliphatic part of the sidechains of Lys98
(VP1), Asn96 (VP1) and Asn214 (VP1) and the hydrophobic
part of the backbone of Tyr192 (VP1). There are also stack-
ing interactions with Tyr210 (VP1) (edge on) and Ile188
(VP1) and polar interactions with polar atoms of the WIN
compound. We note additional hydrophobic character
within this channel that might be commensurate with the
binding of a larger natural pocket factor (the pocket factors
observed in rhinoviruses and polioviruses to date have
aliphatic chains of 5–16 carbon atoms). This difference
might explain some pathological characteristics of this virus
such as its preference for cell-specific membrane compo-
nents, additional to the cellular receptor, as suggested by
the observation that  different fatty acids have distinct
effects on the uncoating of different picornaviruses [41]. An
obvious question is whether a larger pocket factor might
render the virus particularly conformationally labile in the
absence of a pocket factor. Alternatively a longer pocket
factor, reaching up closer to the vicinity of the exposed C
terminus of VP1, may be better able to ‘sense’ the binding
of the integrin receptor. It is also interesting for the mecha-
nism of uncoating that the mouth WIN is located at the
interprotomer interface near the pseudo-threefold axis, a
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Figure 5
Surface characteristics represented by GRASP [59]. (a–c) CAV9.
(d–f) CBV3. Backbone worms are coloured as in Figure 2, and
protomer units are bordered in black. WIN compounds or pocket
factors are shown as white ball-and-stick models. Parts (a) and (d) are
contrasted by radial depth-cueing. Parts (b) and (e) show charged
residues: blue, positive; red, negative. Part (c) shows CAV9 residues
coloured by the extent of conservation among CAV9 and CBVs; most
variable residues are white and strictly conserved residues are shown
in magenta. Part (f) shows CBV3 residues coloured by conservation
amongst CBVs. The residue number subscript defines the viral protein
(e.g. 2841 is residue 284 of VP1).
possible weak point of the capsid. It is usually assumed that
removal of the pocket factor primes the capsid for uncoat-
ing, alternatively the high concentration of lipid on the cell
surface might facilitate lipid exchange with the pocket
factor, destabilising the virion. 
Ions
There are five spheres of nonprotein density on the five-
fold axis that resemble ions (Figure 7b). The two
strongest regions of density are ~123 Å and ~112 Å from
the centre of the virus. The first is surrounded by the
sidechain oxygen atoms of fivefold-related VP3 Thr4 (dis-
tance 3.5 Å) and Asn6 (distance 3.7 Å). Chloride has been
suggested as a likely candidate for an ion in a similar posi-
tion in HRV14 [27], although this would be too light to
account for the density we observe. The second ion is
4.1 Å from each of the five symmetry-related C9 atoms of
the myristylated VP4 N termini. The three weaker regions
of density are ~153 Å, ~148 Å and ~139 Å from the centre
of the virus and could also be ions, perhaps with lower
occupancy. The ions at 153 Å and 148 Å lie next to
residues in the DE loop of VP1, but no direct interactions
between ion and protein are visible. However, the nearest
protein atom to both ions is the sidechain oxygen of
Asp136 (VP1) at a distance of 4.1 Å and 5.0 Å, respec-
tively. A putative ion interacting with the DE loop of VP1
has also been found in CBV3, human rhinoviruses and
Mengo virus [20,42,4]; in HRV16 (Figure 7c) a zinc ion
was putatively assigned at a radius of 152 Å, because of
coordination by histidine residues [33,42]. The fivefold
ion at 139 Å from the virus centre is 6.3 Å from the main-
chain oxygen of Gly175 on the EF loop of VP1.
There is density resembling an ion on the icosahedral
threefold axis at ~145 Å radius. The ion is 3.7 Å away from
the mainchain oxygen of Pro202 (VP3), in a similar posi-
tion to an ion found on the threefold axes of CBV3 and
HRV14 where interaction is seen with a conserved
aspartate residue.
Fivefold axis structure and uncoating
In common with other picornavirus structures [26], CAV9
contains a myristoyl group covalently linked to the N termi-
nus of VP4, with the symmetry-related copies clustering
around the fivefold axis (Figure 7a). It has been proposed
that during uncoating the RNA and VP4 leave through the
fivefold channel [37], that the myristylated VP4 N terminus
is involved in interaction with the host cell membrane, and
that the previously buried N-terminal region of VP1
becomes exposed [43]. For most enteroviruses and rhino-
viruses this region of VP1 is not visible in the structure,
however, in CAV9 the N-terminal peptide is resolved and
its position, under the N terminus of VP4 on the fivefold
axis, is consistent with this hypothesis. The myristoyl group
might also stabilise the N-terminal VP3 β barrel and is
essential for assembly in at least some picornaviruses [43].
CAV9 provides a continuous model for the VP1 N termi-
nus of an enterovirus (Figure 7b) and as there is also a
complete model of the VP1 N terminus for rhinovirus
HRV16 (Figure 7c) [33] we can compare the structures at
the fivefold axis of the two genera. The VP1 N terminus
of CAV9 adopts an extended conformation similar to the
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Figure 6
WIN 51711 molecules. (a) The 2Fo–Fc maps for the pocket and mouth
WIN molecules are contoured at 1σ and 0.5σ, respectively. The WIN
compounds are depicted as ball-and-stick models. The protein
backbone is represented as a worm, colour-coded as in Figure 2.
Residues and water molecules within 4 Å of the WIN molecules are
shown as stick models and spheres, respectively. The residue number
subscript defines the viral protein (e.g. 981 is residue 98 of VP1). The
inset shows the chemical structure of WIN 51711. (b) A close-up of
the mouth WIN 51711 molecule and surrounding protein. Figure
generated using BOBSCRIPT [52,53] and Raster3D [54].
unassigned electron density observed for polioviruses [24],
which contrasts with the N-terminal helix of HRV16 VP1.
The difference in the direction of the two antiparallel
β strands from each VP4 N terminus breaks the ten-
stranded β barrel of HRV16 (Figure 7c) into five separate
β sheets in CAV9 (Figure 7b). So far, all the visible fea-
tures of this region of the enteroviruses are consistent with
those of CAV9, and the features of the other rhinoviruses
are consistent with those of HRV16.
However, the fact that the sequences of the first ten
residues of VP1 and VP4 are fairly conserved among cox-
sackieviruses and rhinoviruses makes us wonder what
causes the above structural difference. Although a  three-
residue-long deletion in CAV9 and CBV3 compared with
HRVs around residue 12 (VP1) may dictate the extended
nature of the coxsackievirus VP1 N terminus, polioviruses
have an insertion instead. The helical wheel representation
of the VP1 N terminus of CAV9 shows clear amphipathicity
(data not shown) as demonstrated for CBV3 and
polioviruses [43]; this putative amphipathic helix has been
proposed to attach to cell membranes when externalised.
This explains the conservation of the VP1 N terminus, but
not the observed structural difference at the base of the
fivefold axis. The disorder of this structure widely shown
among the enteroviruses and rhinoviruses suggests that the
above structural difference might not be a strict characteris-
tic of each genus, and these viruses may show considerable
conformational heterogeneity even in the resting state. A
defining feature of enteroviruses is their greater acid stabil-
ity and indeed the first seven-residue segment of CAV9
VP1 (Gly-Asp-Val-Glu-Glu-Ala-Ile) is more acidic than that
of HRV16 (Asn-Pro-Val-Glu-Arg-Tyr-Val) so that it might
require a lower pH to switch it into a helical conformation.
However, HRV14 and HRV3 also have acidic VP1
N termini and so this is unlikely to be a general explanation.
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Figure 7
The vicinity of the fivefold axis. (a) A close-up of one myristoyl group,
shown as a ball-and-stick model, and a portion of the 2Fo–Fc electron-
density map contoured at 1σ. Other myristoyl groups are shown as sticks.
Protein subunit backbones are depicted as in Figure 6. Residues and
water molecules within 4 Å of the myristoyl molecules are shown as stick
models and spheres, respectively. Schematic representations of (b) CAV9
and (c) HRV16. The fivefold axis runs vertically through the centre of each
figure. Two copies of VP1, WIN compounds and pocket factor (labelled
PF), five copies each of VP1, VP3 and VP4 N-terminal strands, one copy
of the VP3 N-terminal loop, and fivefold axis related putative ions are
shown. Residues close to ions are also shown in ball-and-stick
representation with atoms in standard colours. (d) Stereoview detailed
structure of CAV9 viewed from the centre of the virion. The backbone and
sidechain atoms are shown as thick and thin sticks, respectively. The
residue number subscript defines the viral protein (e.g. 284 is residue 28
of VP4). Figure generated using BOBSCRIPT [52,53] and Raster3D [54].
It was recently reported that antisera raised against CAV9
reacted to synthetic peptides with the VP3 N-terminal
sequence, as well as to VP1 N-terminal peptides [44].
This suggests that the VP3 N terminus might transiently
externalise along with the VP1 and VP4 N termini during
immunisation. As our structure has confirmed that the
CAV9 VP3 N terminus has a location and conformation
similar to those of other picornaviruses, this report implies
that conformational changes larger than those previously
proposed [45] occur and that these might be common to
other picornaviruses.
Biological implications
Coxsackievirus A9 (CAV9) is a small icosahedral single-
stranded RNA virus that belongs to the genus
Enterovirus of the family Picornaviridae. The capsid
enclosing the RNA genome comprises 60 copies of four
viral proteins, VP1–4, arranged with pseudo T = 3 sym-
metry. CAV9 is a clinical pathogen, linked with a variety
of illnesses. It is the only CAV so far sequenced that pos-
sesses an RGD motif (as part of a 15-residue extension at
the C terminus of VP1). Binding to integrin αvβ3 has been
established, although cell-type-specific, and the virus
maintains the use of an alternative unidentified entry
route. In the crystal structure of CAV9 reported here,
the VP1 C terminus in the vicinity of the RGD motif dis-
plays characteristic mobility on the virion outer surface.
In addition, sequence comparison in the surface depres-
sions suggests unidentified alternative receptor(s) differ-
ent from those identified for coxsackie B viruses (CBVs).
Enteroviruses and rhinoviruses have a hydrophobic pocket
inside the β barrel of VP1, which is often occupied by fatty-
acid-like electron density. This pocket is pharmaceutically
important because antiviral drugs (e.g.  those named WIN
compounds) bind here and inhibit virus uncoating. An
unexpected finding for CAV9 is the presence of additional
electron density at the mouth of the pocket, consistent with
a second WIN molecule, suggesting that a larger natural
compound might bind here. This finding has implications
for the design of new antiviral compounds and novel strate-
gies for the investigation of uncoating. 
The features along the fivefold axis are consistent with
the hypothesis that the VP1 N termini and VP4 exit
through the fivefold axis, permitting the extrusion of the
RNA genome. Differences between the innermost struc-
tures of the CAV9 and HRV16 fivefold axes provide a
basis for the discussion of uncoating mechanisms.
Materials and methods
Virus purification and crystallisation
The conditions of growth, purification and crystallisation of CAV9 are
given in [46], except that 10 µg/ml of WIN 51711 (disoxaril), dispersed
in dimethylsulphoxide beforehand, was present during propagation,
purification and crystallisation. CAV9 crystals display rhombic plate habit
and belong to space group C2 (pseudo I222, see below) with unit-cell
dimensions of a = 487.3 Å, b = 358.1 Å, c = 305.7 Å, α = γ = 90°,
β = 128.10°. There is 30-fold noncrystallographic symmetry as the crys-
tallographic twofold axis coincides with an icosahedral twofold axis.
The capsid-encoding region of the full-length CAV9 cDNA clone (Griggs
strain, plaque-purified three times in LLC-Mk2 cells prior to cloning [1])
was resequenced. Sequencing primers included four sense primers,
which annealed to positions 547–567, 1179–1198, 1921–1940 and
2413–2433 of the CAV9 genome, as well as two antisense primers,
which annealed to positions 3180–3199 and 3720–3739. 
Data collection and reduction
A data set of 41.1% completeness containing 290,000 unique reflec-
tions was collected at the Synchrotron Radiation Source (SRS) Dares-
bury; 33 images were collected on station 7.2 and 59 on station 9.6
with the wavelengths of 1.488 and 0.87 Å, respectively. Statistics on
the merged data are shown in Table 1. The exposure times were in the
order of 120 s per image. The data were autoindexed and scaled using
the HKL package programs DENZO and SCALEPACK [47]. The sym-
metry of the intensity data indicated that the space group was C2 and
the volume of the unit cell was consistent with a crystallographic asym-
metric unit comprising half the virus particle. 
Structure determination
Measured diffraction intensities were converted to structure-factor ampli-
tudes using the CCP4 program TRUNCATE [48]. In the space group C2
with the virion centre lying on the b axis (the crystallographic twofold axis
in the standard definition), determination of the orientation of the virus par-
ticle around this axis is sufficient to solve the molecular replacement
problem (as the position of the centre of the virion along b is arbitrary).
Calculation of a self-rotation function (program X-PLOR [49]) using data
from 15–5.5 Å resolution, with a minimum and maximum integration
radius of 30 Å and 270 Å, respectively, revealed the orientation of the
virion around b. Correlation analysis in reciprocal space using the appro-
priate portion of the CBV3 virion as a phasing model defined this orienta-
tion very precisely, giving a peak at 41.76° rotation from the standard
orientation, 39σ above the background level. The initial R factor (see
Table 1 for definition) for the orientated CBV3 virus model was 41%, with
a correlation coefficient of 43%, and a 30-fold averaged 2Fo–Fc map was
of good enough quality to build in the CAV9 sequence. Model building
was carried out using the interactive graphics program FRODO [50] on
an Evans and Sutherland workstation and the structure was refined in X-
PLOR [49], using strict 30-fold noncrystallographic symmetry constraints
together with a solvent correction. Positional and B-factor refinement was
alternated with rebuilding for two rounds, at which point a 2Fo–Fc map
was calculated and used as the starting point for extensive cycles of 30-
fold noncrystallographic averaging. The model was then rebuilt again;
WIN 51711, the myristoyl group, more residues of VP1 and VP4 and 448
water molecules were included. Forty cycles of 30-fold averaging were
then performed, which converged to give an averaging correlation coeffi-
cient of 89% (both WIN compounds were omitted from the phasing
model for these calculations). The final R factor for the model was 16.9%
and 87% of the residues lie in the most favoured region of the Ramachan-
dran plot. Statistics on the final model are presented in Table 1.
Accession numbers
The coordinates have been deposited with the Brookhaven Protein
Data Bank (accession code 1D4M).
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